![Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S. | Fierce Pharma Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S. | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1573140546/Truxima-MASTER-FAMILY_RGB%5B2%5D.png/Truxima-MASTER-FAMILY_RGB%5B2%5D.png?VersionId=EwcgpNctcGgX_.1ejh7QfzCJJaxbeAJ7)
Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S. | Fierce Pharma
Arthritis Ireland - The European Medicines Agency Safety Committee (PDCO) is currently assessing the educational materials available for patients taking rituximab (MabThera and its biosimilars). The objective of these materials (patient alert
![NICE accepts rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis NICE accepts rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis](https://cached.imagescaler.hbpl.co.uk/resize/scaleWidth/952/cached.offlinehbpl.hbpl.co.uk/news/2MM/NICE-Clinical-Guideline-TA308-rituximab-MabThera-glucocorticoids-anti-neutrophil-cytoplasmic-vasculitis-20140326023942208.jpg)